AnGes,Inc. (4563.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.6x

Market Cap

JPY 13.84B

MomentumView details →

1D Return

+0.00%

YTD Return

−36.07%

RSI (14)

30.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.6x

Market Cap

JPY 13.84B

RSI (14)

30.6

MomentumView details →

1D Return

+0.00%

YTD Return

−36.07%

ProfitabilityView details →

Gross Margin

36.64%

Net Margin

−586.16%

EBITDA Margin

−582.51%

ROE (TTM)

−166.55%

ROA (TTM)

−94.78%

Asset Turnover

0.15x

GrowthView details →

Revenue YoY

+35.93%

EPS YoY

+87.30%

FCF YoY

—

Revenue CAGR 3Y

+135.40%

EPS CAGR 3Y

+87.92%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

1.96x

Quick Ratio

1.85x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

908.00M

Net Income (TTM)

−4.96B

Op. CF (TTM)

—

Next earningsNov 6, 2026 →

Latest newsMore news →

AnGes announced progress on its HGF gene therapy product, having completed clinical trials in the US and moving to the preparation stage for a Biologics License Application (BLA) submission to the FDA, with a plan for staged submission without a Pre-BLA Meeting.19d ago

AnGes resolved to issue the 47th and 48th share subscription rights and the 2nd unsecured convertible bond-type share subscription rights bonds, allocating them to a fund managed by Growth Partners, to raise a total of 8.5 billion yen, and also entered into a business alliance agreement with the same fund.19d ago

Similar companies

Renascience Inc.4889.T RaQualia Pharma Inc.4579.T TAIKO PHARMACEUTICAL CO.,LTD.4574.T STELLA PHARMA CORPORATION4888.T CanBas Co.,Ltd.4575.T MediciNova,Inc.4875.T Find similar companies →

Latest newsMore news →

AnGes announced progress on its HGF gene therapy product, having completed clinical trials in the US and moving to the preparation stage for a Biologics License Application (BLA) submission to the FDA, with a plan for staged submission without a Pre-BLA Meeting.19d ago AnGes resolved to issue the 47th and 48th share subscription rights and the 2nd unsecured convertible bond-type share subscription rights bonds, allocating them to a fund managed by Growth Partners, to raise a total of 8.5 billion yen, and also entered into a business alliance agreement with the same fund.19d ago